Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vivus Will Cut Population In Qnexa Resubmission

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech announces it will resubmit its obesity drug by the end of October, two months ahead of schedule, after a meeting with FDA.
Advertisement

Related Content

Regulatory Update For Qnexa Could Signal A Change In The Obesity Landscape
Regulatory Update For Qnexa Could Signal A Change In The Obesity Landscape
Vivus Resubmits Qnexa, But Limits Its Market Opportunity
Vivus Resubmits Qnexa, But Limits Its Market Opportunity
Orexigen Agreement On Contrave CV Trial Hints At FDA’s Thinking On Obesity
Orexigen Resurrects Contrave With New Trial Agreement With FDA
Arena Gains Evidence To Address FDA Concerns About Lorcaserin, But More Still Needed
Arena Gains Evidence To Address FDA Concerns About Lorcaserin, But More Still Needed
Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Cmte On CV Risk
Vivus Would Market Qnexa With Pregnancy Category X Designation If Approved

Topics

Advertisement
UsernamePublicRestriction

Register

PS072775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel